Artificial intelligence and digital pathology firm PathAI has unveiled the launch of the Precision Pathology Network (PPN), a first-of-its-kind network of digital anatomic pathology laboratories, which aims to platform expands access to latest AI products, unlock real-world data value, and fuel collaborative research with biopharma across a broad network.
The PPN is designed to enable early access to the latest AI-powered pathology solutions developed by PathAI in collaboration with the biopharma industry, enable participating laboratories to monetise real-world pathology data, support biopharma sponsored evidence generation studies, and enable novel clinical development strategies leveraging AI-pathology.
The PathAI Precision Pathology Network leverages the company’s AISight IMS platform as its technological backbone and provides members:
- Early access to AI innovations: Together, with biopharmaceutical partners, members will receive prioritised access to new algorithm products being developed by PathAI. These next-generation algorithm products will support the future of precision biomarker testing and patient care, empowering PPN laboratories to offer these solutions immediately once new diagnostic digital tools are commercially available. PathAI currently has a pipeline of such solutions under development with leading pharma partners in the oncology space.
- New revenue pathways through real world data: Facilitated through PathAI and its strategic partners, the PPN provides a standardised framework for member laboratories to securely contribute de-identified pathology data - including whole slide images, pathology reports, and other clinical and molecular data - for use in translational research and collaborative projects with biopharma.
- Unlock Revenue opportunities in high-quality evidence generation studies: Achieving 'evidence generation readiness' is crucial, demanding consistent data collection and strict protocol adherence. While PathAI doesn't create readiness, it says it will demystify the process, empowering laboratories to confidently compete for and win significant evidence generation business.
- Accelerating therapeutic clinical development with AI-powered pathology: Ability to leverage PathAI’s proprietary algorithms, such as MET-Predict, which identifies MET-amplified tumours with high accuracy, into PPN-member workflows to support patient identification and screening for clinical trial enrolment.
- Access to advanced ai precision medicine tools and development frameworks: Members will benefit from the ability to access PathAI's market-leading biomarker discovery Explore product line via AISight, as well as the company’s PLUTO foundation model, enabling novel biomarker research, grant collaboration, and even custom model co-development opportunities.
The Precision Pathology Network connects a diverse group of leading healthcare and research institutions. By bringing together industry, academia, and clinical leaders in pathology, the PPN is aiming to establish a broad foundation for innovation in digital diagnostics and data-driven disease insights. Further, by connecting laboratories via a unified digital platform, AISight, the PPN accelerates cross-institution collaboration, helping standardise quality, and ultimately driving forward precision medicine by connecting pathology labs to biopharma R&D in a networked ecosystem.
“We are thrilled to launch the PathAI Precision Pathology Network as a major step toward advancing precision diagnostics,” said Andy Beck, MD, PhD, co-founder and CEO of PathAI. “PathAI is the leading digital pathology company working deeply with the biopharma industry to accelerate their precision medicine goals using AI-powered pathology, who also works with a large network of pathology laboratories who are on the cutting edge and implementing digital within their workflows. This first-of-its-kind network will play a vital role in advancing precision diagnostics and accelerating the adoption of AI in pathology, working to ensure that these innovations translate into improved patient outcomes worldwide.”
PathAI invites additional pathology laboratories and biopharmaceutical organizations to learn more about joining the PPN. Interested laboratories and partners can visit the landing page to explore how the PPN can support their clinical and research goals.